NUVL Key Statistics, Chart & Performance
The current stock price of NUVL is 100.59 USD. In the past month the price decreased by -4.16%. In the past year, price increased by 24.52%.
NUVL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About NUVL
Company Profile
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 218 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Company Info
NUVALENT INC-A
One Broadway, 14Th Floor
Cambridge MASSACHUSETTS US
CEO: James R. Porter
Employees: 218
Phone: 18573577000
NUVALENT INC-A / NUVL FAQ
What does NUVALENT INC-A do?
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 218 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Can you provide the latest stock price for NUVALENT INC-A?
The current stock price of NUVL is 100.59 USD. The price increased by 0.21% in the last trading session.
Does NUVL stock pay dividends?
NUVL does not pay a dividend.
What is the ChartMill rating of NUVALENT INC-A stock?
NUVL has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists NUVL stock?
NUVL stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of NUVALENT INC-A (NUVL)?
NUVALENT INC-A (NUVL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.32).
What is NUVALENT INC-A worth?
NUVALENT INC-A (NUVL) has a market capitalization of 7.77B USD. This makes NUVL a Mid Cap stock.
NUVL Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NUVL. When comparing the yearly performance of all stocks, NUVL is one of the better performing stocks in the market, outperforming 87.11% of all stocks.
NUVL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NUVL. While NUVL has a great health rating, there are worries on its profitability.
NUVL Financial Highlights
Over the last trailing twelve months NUVL reported a non-GAAP Earnings per Share(EPS) of -5.32. The EPS decreased by -53.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.93% | ||
| ROE | -45.12% | ||
| Debt/Equity | 0 |
NUVL Forecast & Estimates
24 analysts have analysed NUVL and the average price target is 142.68 USD. This implies a price increase of 41.84% is expected in the next year compared to the current price of 100.59.